Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Trump Says Anthropic No Longer Seen as National Security Threat 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
NEWARK, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, today announced that senior management will present a corporate update at the Biotech Showcase 2016 being held in San Francisco on January 11-13.
| Biotech Showcase 2016 – CymaBay Presentation Details | |
| Date: | Tuesday, January 12 |
| Time: | 3:00pm Pacific Time |
| Place: | Parc 55 San Francisco |
| Webcast: | http://ir.cymabay.com/events |
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. MBX-8025 is a potent, selective, orally active PPARδ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has two ongoing clinical studies for MBX-8025 including a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia and a Phase 2 study in patients with primary biliary cholangitis.
For additional information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
